Chlamydia is a commonly occurring sexually transmitted infection. It is usually treated by antibiotic medications such as azithromycin and erythromycin. However, if the infection is not treated, it can lead to severe or chronic conditions. In developed and developing countries, spending on chlamydia infection treatment is increasing due to rise in awareness about complications related to the disease and surge in spending on personal health care. According to the United Nations International Conference on Population & Development held in Cairo, global statistics reveal a high burden of maternal and infant morbidity and mortality. Rise in prevalence of chlamydia infections among pregnant women is leading to problems such as miscarriage, stillbirth, ectopic pregnancy, preterm births, neonatal conjunctivitis, neonatal pneumonia, and other potential effects. This rise in mortality has been a major factor responsible for increased research on understanding the link between pregnancy and chlamydia infections. This has led to rise in number of screenings for chlamydia infections in pregnant women, which in turn fuels the growth of the global chlamydia diagnostics market. Government initiatives and favorable reimbursements for chlamydia screening are factors anticipated to increase the rate of chlamydia screening in the next few years. These favorable reimbursement policies are expected to propel the global chlamydia diagnostics market during the forecast period.
Demand for diagnostic tests that are efficient in providing rapid results with high sensitivity and specificity is significantly high among physicians, diagnostic labs, and hospitals across the world. Demand for cost-effective therapeutics is also high. Cost of diagnostic tests and therapeutics has a major impact in emerging economies, where inexpensive diagnostic tests and therapeutics are preferred. Demand for inexpensive diagnostic tests and therapeutics for the treatment of chlamydia infections is high in emerging markets such as India, China, and Brazil, as several substitutes for diagnostic tests are available in the chlamydia diagnostics market. Awareness about chlamydia infection diagnostic tests is extremely low in countries in Africa. Hence, companies are facing challenges with regards to chlamydia diagnostics market penetration. This, in turn, restrains the chlamydia diagnostics market in the region.
The global chlamydia diagnostics market can be segmented based on test type, end-user, and region. In terms of test type, the chlamydia diagnostics market can be segmented into nucleic acid amplification tests (NAAT), direct fluorescent tests, and others. Based on end-user, the global chlamydia diagnostics market can be segmented into hospitals, specialty clinics, and diagnostic centers. In terms of region, the global chlamydia diagnostics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to continue to dominate the chlamydia diagnostics market during the forecast period. Increase in health care awareness, reimbursement facilities for chlamydia diagnostics along with significant health care spending in overall national budgets, early availability of advanced technologies, and higher penetration of research activities across the country are expected to drive the chlamydia diagnostics market in the region. Asia Pacific has a high incidence rate of infectious diseases such as sexually transmitted diseases, blood infections, and diarrheal infections. Demand for affordable diagnostic kits is high in India and China, followed by countries in Southeast Asia. This is attributed to strong preventive measures adopted by the governments to prevent the spread of infectious diseases. Diagnostic tests that provide faster and specific results at point-of-care and outpatient settings are preferred by physicians in the region. Demand for rapid diagnostic kits is also fueled by the lack of expertise and knowledge about laboratory settings and poor health care infrastructure in the region. Several local governments is Asia Pacific have tie-ups with rapid diagnostic kits manufacturers and depend upon contract manufacturing for regular supply of these kits. Moreover, several patients in the region depend upon government programs for diagnostic tests.
Key players in the global chlamydia diagnostics market are Abbott Laboratories, F Hoffmann-La Roche, Bio Rad laboratories, DiaSorin SpA, Novartis AG, Thermo Fisher Scientific, Danaher Corporation, bioMerieux, Siemens AG, and Becton Dickinson and Company.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.